{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T21:02:43Z","timestamp":1758142963795,"version":"3.44.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.arteri.2025.500819","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T15:03:01Z","timestamp":1748876581000},"page":"500819","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"S1","title":["Estudios de prevenci\u00f3n cardiovascular en poblaci\u00f3n con hipertrigliceridemia"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2230-6556","authenticated-orcid":false,"given":"Ovidio","family":"Mu\u00f1iz-Grijalvo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arteri.2025.500819_bib0115","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.106.637793","article-title":"Triglycerides and the risk of coronaryheart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies","volume":"115","author":"Sarwar","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.arteri.2025.500819_bib0120","first-page":"259","article-title":"Modulaci\u00f3n del PPAR\u03b1 por agentes farmacol\u00f3gicos y naturales y sus implicaciones metab\u00f3licas","volume":"20","author":"Panadero","year":"2008","journal-title":"Clin Invest Arterioscl"},{"key":"10.1016\/j.arteri.2025.500819_bib0125","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: Primary pre-vention trial with gemfibrozil in middle-aged men with dyslipidaemia","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2025.500819_bib0130","doi-asserted-by":"crossref","first-page":"410-418","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2025.500819_bib0135","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/01.CIR.102.1.21","article-title":"Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study","volume":"102","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.arteri.2025.500819_bib0140","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"The FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.arteri.2025.500819_bib0145","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2025.500819_bib0150","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"N Engl J Med"},{"year":"2014","series-title":"Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease","key":"10.1016\/j.arteri.2025.500819_bib0155"},{"year":"2000","series-title":"Triglyceride Lowering Drugs. In: Endotext [Internet]","author":"Feingold","key":"10.1016\/j.arteri.2025.500819_bib0160"},{"key":"10.1016\/j.arteri.2025.500819_bib0165","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.jacc.2013.07.023","article-title":"Relationship of lipoproteins to cardiovascular events: The AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL\/High Triglycerides and Impact on Global Health Outcomes)","volume":"62","author":"Guyton","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arteri.2025.500819_bib0170","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurheartj\/eht055","article-title":"HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin\/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment","volume":"34","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arteri.2025.500819_bib0175","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1177\/0897190018824485","article-title":"Knowledge, perceptions, and patterns of fish oil use in cardiac patients","volume":"33","author":"Hilleman","year":"2019","journal-title":"J Pharm Pract."},{"key":"10.1016\/j.arteri.2025.500819_bib0180","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jacc.2020.11.060","article-title":"Cardiovascular Impact of Nutritional Supplementation with Omega-3 Fatty Acids: JACC Focus Seminar","volume":"77","author":"Weinberg","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arteri.2025.500819_bib0185","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2025.500819_bib0190","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.arteri.2025.500819_bib0195","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa1203859","article-title":"n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia","volume":"367","author":"Bosch","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2025.500819_bib0200","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1161\/CIRCULATIONAHA.110.948562","article-title":"OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction","volume":"122","author":"Rauch","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.arteri.2025.500819_bib0205","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJMoa1804989","article-title":"Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus","volume":"379","author":"Bowman","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2025.500819_bib0210","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1811403","article-title":"Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer","volume":"380","author":"Manson","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2025.500819_bib0215","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.arteri.2025.500819_bib0220","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J."}],"container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916825000622?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916825000622?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T15:25:23Z","timestamp":1758122723000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0214916825000622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":22,"alternative-id":["S0214916825000622"],"URL":"https:\/\/doi.org\/10.1016\/j.arteri.2025.500819","relation":{},"ISSN":["0214-9168"],"issn-type":[{"type":"print","value":"0214-9168"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Estudios de prevenci\u00f3n cardiovascular en poblaci\u00f3n con hipertrigliceridemia","name":"articletitle","label":"Article Title"},{"value":"Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arteri.2025.500819","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author. Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Sociedad Espa\u00f1ola de Arteriosclerosis.","name":"copyright","label":"Copyright"}],"article-number":"500819"}}